Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | TTR | P02766 | 1/20 | 0.34 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31437950 | 1.00 | MGLL (0.39) | MGLLEPHX2ABL1PDE2AIDO1 | |
| SCHEMBL491621 | 0.85 | EPHX2 (0.50) | MGLLEPHX2ABL1PDE2ACA1 | |
| SCHEMBL22683815 | 0.81 | APP (0.45) | MGLLABL1ENPP2CA1CA2 | |
| SCHEMBL29952898 | 0.81 | APP (0.45) | MGLLABL1ENPP2CA1CA2 | |
| SCHEMBL29953617 | 0.80 | MGLL (0.38) | MGLLEPHX2ABL1PDE2AENPP2 | |
| SCHEMBL29955486 | 0.80 | TTR (0.42) | MGLLABL1ENPP2CA1CA2 | |
| SCHEMBL2409490 | 0.80 | TTR (0.42) | MGLLABL1ENPP2CA1CA2 | |
| SCHEMBL20638904 | 0.79 | ENPP2 (0.41) | MGLLABL1PDE2AENPP2CA1 | |
| SCHEMBL29953216 | 0.79 | ENPP2 (0.41) | MGLLABL1PDE2AENPP2CA1 | |
| SCHEMBL29953648 | 0.78 | MGLL (0.39) | MGLLEPHX2ABL1PDE2AENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702401-B2 | Compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2023-07-18 | — | — | US | disclosed |
| US-20220000847-A1 | Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC (US) | 2022-01-06 | — | — | US | disclosed |
| US-11053216-B2 | Compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2021-07-06 | — | — | US | disclosed |
| CN-107531705-B | Bicyclic ketone sulfonamide compounds | 美国安进公司 | 2020-09-18 | — | — | CN | disclosed |
| EP-3089971-B1 | COMPOUNDS AND METHODS OF USE | MEDIVATION TECH LLC (US) | 2020-07-29 | — | — | EP | disclosed |
| US-10668067-B2 | Pyridine sulfonamides | AMGEN INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-10668067-B2 | Pyridine sulfonamides | AMGEN INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-20200071296-A1 | Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2020-03-05 | — | — | US | disclosed |
| US-20190167682-A1 | PYRIDINE SULFONAMIDES | AMGEN INC. (US) | 2019-06-06 | — | — | US | disclosed |
| US-20190167682-A1 | PYRIDINE SULFONAMIDES | AMGEN INC. (US) | 2019-06-06 | — | — | US | disclosed |
| EP-2483290-A1 | CYCLIC PEPTIDE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | Intermune, Inc. (US) | 2012-08-08 | — | — | EP | disclosed |
| US-20110218192-A1 | Inhibitors Of Beta-Secretase | VITAE PHARMACEUTICALS, INC. (US) | 2011-09-08 | — | — | US | disclosed |
| US-20110218192-A1 | Inhibitors Of Beta-Secretase | VITAE PHARMACEUTICALS, INC. (US) | 2011-09-08 | — | — | US | disclosed |
| EP-2324032-A2 | INHIBITORS OF BETA-SECRETASE | Vitae Pharmaceuticals, Inc. (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20110081315-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-20110081315-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| WO-2011038293-A1 | CYCLIC PEPTIDE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-03-31 | — | — | WO | disclosed |
| WO-2011038293-A1 | CYCLIC PEPTIDE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-03-31 | — | — | WO | disclosed |
| WO-2010021680-A2 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| WO-2010021680-A2 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218192-A1 | Inhibitors Of Beta-Secretase | BACE1, BACE2, APP | MGLL 1603/4885EPHX2 1305/4885ABL1 3137/4885 |
| US-20220000847-A1 | Compounds and Methods of Use | TGFB2, TGFB1, HDGF | MGLL 3064/4885EPHX2 1597/4885ABL1 1120/4885 |
| US-11702401-B2 | Compounds and methods of use | TGFB2, TGFB1, HDGF | MGLL 3064/4885EPHX2 1597/4885ABL1 1120/4885 |
| US-20190167682-A1 | PYRIDINE SULFONAMIDES | TRPV1, TRPA1, TRPV5 | MGLL 4282/4885EPHX2 3456/4885ABL1 259/4885 |
| US-20200071296-A1 | Compounds and Methods of Use | TGFB2, TGFB1, HDGF | MGLL 3064/4885EPHX2 1597/4885ABL1 1120/4885 |
| US-10668067-B2 | Pyridine sulfonamides | TRPV1, TRPA1, TRPV5 | MGLL 4282/4885EPHX2 3456/4885ABL1 259/4885 |
| US-11053216-B2 | Compounds and methods of use | TGFB2, TGFB1, HDGF | MGLL 3064/4885EPHX2 1597/4885ABL1 1120/4885 |
| US-20110081315-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, EIF4A2 | MGLL 3415/4885EPHX2 1977/4885ABL1 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.